Abstract：
Monkeypox is a zoonosis that re-emerged in 2022, generating cases in non-endemic countries for the disease and creating a public health issue. The rapid increase in the number of cases kindles a need for quick, inexpensive diagnostic tests for the epidemiological control of the disease. The high cost of molecular tests can make this control more difficult to access in poorer regions, with immunological tests being a more viable option. In this mini-review, a search was conducted in the main databases for peptide and protein options that could be used in the development of serological diagnostic tests. Nine viable registres were found, and seven were selected (two patents and five studies). The main studies used the B21R peptide sequence as it is a high immunogenic epitope. In addition, studies on the improvement of these sequences were also found to avoid cross-reactions against other viruses of the same family, proposing a rational approach using multiepitope recombinant proteins. These approaches demonstrated high sensitivity and specificity values and are seen as viable options for developing new tests. New effective serological testing options, when combined with awareness, disease surveillance, early diagnosis, and rapid communication, form a set of key strategies used by health systems to control the spread of the monkeypox virus.
摘要：
猴痘是一种人畜共患病，于2022年重新出现，在非地方病国家产生了这种疾病的病例，并造成了公共卫生问题。病例数量的迅速增加引发了对快速的需求，用于疾病流行病学控制的廉价诊断测试。分子测试的高成本会使这种控制在较贫穷的地区更难获得，免疫测试是一个更可行的选择。在这个小型审查中，在主要数据库中搜索了可用于开发血清学诊断测试的肽和蛋白质选项。发现了9个可行的注册人，并选择了七项(两项专利和五项研究)。主要研究使用B21R肽序列,因为它是高免疫原性表位。此外,对这些序列改进的研究也被发现可以避免对同一家族的其他病毒的交叉反应，提出了一种使用多表位重组蛋白的合理方法。这些方法表现出高灵敏度和特异性值，被视为开发新测试的可行选择。新的有效血清学检测选项，当与意识相结合时，疾病监测,早期诊断,和快速的沟通，形成一套卫生系统用来控制猴痘病毒传播的关键策略。
